Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Cellmark Consolidates Nashville Branch into Dallas Facility

NEW YORK (GenomeWeb News) – Orchid Cellmark said today that it will begin to consolidate its Nashville, Tenn., forensics testing operations into its Dallas, Texas, facility within the month.

The company expects to realize approximately $1.4 million in annual cost savings from operational efficiencies, reduction in lease and equipment expenses, and increased scalability following the consolidation.

According to a company spokesperson, approximately 25 staffers are located at the Nashville facility. All of them will be offered the opportunity to transfer to Dallas, and Orchid expects that a number of the workers will relocate. Overall it plans to add at least 20 new positions at the Dallas facility to support the increased workload.

Orchid President and CEO Thomas Bologna said in a statement that the consolidation of the company's Nashville operations into Dallas "will enhance our US-based forensics testing efficiencies and scalability, while bringing all of our forensics operations under one roof."

Bologna added that the company currently processes most of its forensic casework samples in Dallas, and that the larger facility in that city allows Orchid to add space and equipment to accommodate added business from Nashville.

"This consolidation makes sense for a number of strategic, financial, and pragmatic reasons, and represents the latest in our ongoing initiatives to provide high-quality DNA forensic testing services in an ever-increasing cost-effective structure," Bologna said.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.